16 or 24 weeks of peginterferon alpha-2a (40KD) (PEGASYS(R)) plus ribavirin (RBV) (COPEGUS(R)) in patients with HCV genotype 2 or 3 and bridging fibrosis or cirrhosis: Results from a large, randomised multinational study (ACCELERATE)

Saved in:
Bibliographic Details
Published in:Journal of clinical virology 2006-01, Vol.36, p.S49-S49
Main Authors: Zeuzem, S, Pappas, S, Nyberg, L, Greenbloom, S, Gibas, A, Bacon, B, Godofsky, E, Harley, H, Bronowicki, J, Lin, A, Soman, A, Shiffman, M
Format: Article
Language:English
Subjects:
Hepatitis C virus
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1386-6532